Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more

Blog

What causes breast cancer?

It may be difficult to know exactly what causes breast cancer, but studies show that it may be connected to various risk factors. Beyond having a genetic link, breast cancer may also be related to hormonal complexities and environmental exposures.

In the United States alone, the average risk of women developing breast cancer sometime in their life is about 13%

Genetic factor

Genetic mutations, particularly in the BRCA1 and BRCA2 genes, significantly heighten the risk of developing breast cancer. These genes typically act as guardians, ensuring cells grow and divide correctly. 

However, when mutations occur, this regulatory mechanism falters, leading to an increased likelihood of cancer. People with these mutations inherit a higher susceptibility to breast cancer, making understanding their genetic makeup crucial.

Screening for such mutations enables proactive measures, such as increased surveillance and preventative interventions, to mitigate the elevated risk.

Hormonal changes

Fluctuations of hormones, particularly estrogen and progesterone, are interconnected with the story of breast cancer. These hormones stimulate the growth of normal breast cells. However, when this regulation goes awry - such as during periods of hormonal imbalance or prolonged exposure to high hormone levels - it can foster an environment conducive to the development of cancer. 

Hormone-receptor-positive breast cancers, which make up a large number of cases, are influenced explicitly by these hormonal dynamics. Mitigating this risk involves lifestyle modifications, including maintaining a healthy weight, regular physical activity, and, in some cases, hormone therapy adjustments under the guidance of healthcare professionals.

Lifestyle choices

The lifestyle you lead and your exposure to environmental factors can contribute to the development of breast cancer risk. Certain lifestyle choices, such as dietary habits, physical activity levels, and exposure to environmental toxins, can influence the likelihood of developing breast cancer. 

Adopting a healthy lifestyle, maintaining a balanced diet, staying physically active, and minimizing exposure to harmful substances can serve as proactive measures to reduce this risk.

Reproductive history

In women, their reproductive journey can play a significant role in breast cancer risk. Factors such as early menstruation, late menopause, pregnancy, and breastfeeding can also contribute to the intricate fabric of risk. 

For instance, early onset of menstruation and late menopause, leading to prolonged exposure to hormones, can elevate risk. Reproductive history is unique for each person, and understanding its nuances allows for personalized risk assessment and tailored preventive strategies.

Age and gender

Age is a crucial determinant in the breast cancer risk equation. The likelihood of developing breast cancer rises with age, with the majority of cases occurring in women aged 50 and older

Additionally, while breast cancer is more common in women, men can also be affected. Understanding these age and gender factors aids in targeted screening efforts, ensuring that those in higher-risk groups receive appropriate attention and interventions.

Other risk factors

Beyond the well-known factors, several additional factors can contribute to higher breast cancer risk. This includes exposure to radiation, certain medical conditions, and the influence of race and ethnicity. 

For instance, women with a family history of breast cancer or specific inherited gene mutations may face an elevated risk. Exploring these less-discussed risk factors expands our comprehension of breast cancer's multifaceted nature, guiding healthcare professionals in developing nuanced and personalized prevention and intervention strategies.

Prevention and early interventions

Proactive measures for breast cancer involve a dual approach - prevention and early detection (and interventions). Scheduling regular screenings, such as mammograms and clinical breast exams, enhances the chances of detecting potential issues at an earlier, more treatable stage. 

Additionally, adopting a healthy lifestyle with a balanced diet, regular exercise, and limiting alcohol consumption can help with prevention. Personalized prevention strategies may include medications or surgical interventions guided by a healthcare professional's expertise for those with specific risk factors.

Innovative tests like RGCC’s liquid biopsy-based tests are crucial in this context. Our liquid biopsy-based test goes beyond traditional screening, aiming to detect cancer at its earliest stages. This test is uniquely tailored to detect cancer in high-risk category people who may not even have noticeable symptoms. 

Furthermore, genetic tests, such as those assessing BRCA1 and BRCA2 mutations, guide treatment decisions and help identify the most effective therapies. 

Our CAMBISeq® test can help trace such genetic mutations that increase your risk for breast cancer. 

Additionally, our Onconomics Plus test can help if you already have a breast cancer diagnosis by assessing the genetic expressions of your cancer cells to guide treatment decisions. At RGCC, our liquid biopsy tests provide comprehensive insights, allowing practitioners to craft individualized treatment plans. 

Our cutting-edge tests are a significant advancement in the journey toward early detection and personalized medicine, providing patients and their practitioners with vital information for informed decision-making and improved outcomes.

Contact us

Discover groundbreaking testing solutions pioneered by RGCC, which enable better breast cancer detection and care. Advances in personalized medicine, coupled with attentive follow-up and tailored interventions, empower us in the effort to reduce the impact of breast cancer.

Our state-of-the-art research centers employ advanced tests and protocols to offer a comprehensive yet personalized view of each patient’s genetics, physiology, and immune profiles. We offer a paradigm shift in cancer care technology and protocols.

Our mission is to empower patients with unique insights into their cancer biology, guiding them toward success in their cancer journey.

Contact us today to start your journey to empowering information for your cancer treatment by contacting us online

Videos

Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.

  • Dr Clayton Bell video cover
    Dr. Clayton Bell, MD | Gathering 2023 Interview

    In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.

    With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.

    Helena Pohlmann video cover
    Helena Pohlmann | Gathering 2023 Interview

    Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.

    Jenny Hrbacek, RN | About RGCC Testing

    Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.

  • Bita Badakhshan
    Bita Badakhshan - RGCC Gathering 2023 Interview

    Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.

    In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.

    Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.

    Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.

    Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.

    Podcast video cover
    Podcast - Innovation in Early Cancer Detection

    Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.

    Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.

    Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.

Videos

Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.

  • Dr Clayton Bell video cover
    Dr. Clayton Bell, MD | Gathering 2023 Interview

    In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.

    With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.

  • Helena Pohlmann video cover
    Helena Pohlmann | Gathering 2023 Interview

    Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.

  • Jenny Hrbacek, RN | About RGCC Testing

    Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.

  • Bita Badakhshan
    Bita Badakhshan - RGCC Gathering 2023 Interview

    Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.

    In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.

    Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.

    Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.

    Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.

    Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/

    RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.

    Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.

    Learn more about RGCC at
    https://rgcc-international.com/

    Follow us on social media to find out the latest news and updates from our experts.

    Facebook: https://www.facebook.com/profile.php?id=61554630098937

    Instagram: https://www.instagram.com/rgcc_north_america/

    LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/

  • Podcast video cover
    Podcast - Innovation in Early Cancer Detection

    Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.

    Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.

    Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.

RGCC
Follow Us
RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
Accreditations
IAS Accreditation
Testing Laboratory
View TL-836 Certificate
EN ISO 22000: 2018
No: 20101200002689
View Certificate
IAS Accreditation
Medical Laboratory
View ML-103 Certificate
ISO 22000: 2018
No: 20101200002689
View Certificate
ISO 45001: 2018
No: 20152220006395
View Certificate
ISO 22716: 2007
No: 20019220006394
View Certificate
CLIA ID Number
99D2283882
View Certificate
College of American Pathologists 
Certificate of Accreditation
CAP#: 9239089 
CLIA#: 99D2283882 
View Certificate
Certificate of GMP Compliance
No. 512863-102689104
View Certificate
Accreditation Certificate of Foreign Cell Processor - Japanese Government
View Certificate
Manufacturing License for Cosmetic Products and Food Supplements under GMP (Good Manufacturing Practices)
Ref. No. 57067
View Details
Hellenic National Organization for Medicines (EOF)
Production License for Investigational ATMPs for Human Use
Ref. No. 7282
View Details
Accreditations
IAS Accreditation
Testing Laboratory
View TL-836 Certificate
EN ISO 22000: 2018
No: 20101200002689
View Certificate
IAS Accreditation
Medical Laboratory
View ML-103 Certificate
ISO 22000: 2018
No: 20101200002689
View Certificate
ISO 45001: 2018
No: 20152220006395
View CertificatePolicy
ISO 22716: 2007
No: 20019220006394
View Certificate
CLIA ID Number
99D2283882
View Certificate
College of American Pathologists 
Certificate of Accreditation
CAP#: 9239089 
CLIA#: 99D2283882 
View Certificate
Certificate of GMP Compliance
No. 512863-102689104
View Certificate
Accreditation Certificate of Foreign Cell Processor - Japanese Government
View Certificate
EOF GMP COSMETICS – SUPPLEMENTS
View Certificate
Call
Text
Email
Map
cross